Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024. In this segment, Dr. Morrison introduces the concept of ...
Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...
hands of a child with juvenile idiopathic arthritis Researchers evaluated the efficacy and safety of abatacept in pediatric patients with polyarticular-course juvenile idiopathic arthritis. ATLANTA — ...
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as seen ...
BCS: Radiological Tests Little Use in Detecting Breast Mets For human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, a subcutaneous formulation of trastuzumab is non-inferior ...
The time required for in-clinic drug administration can substantially affect breast cancer patients' quality of life. Subcutaneous (SC) drug administration, as opposed to intravenous (IV), may reduce ...
Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 ...
Engage: A Survivorship Program to Improve Childhood Cancer Survivors' Self-Efficacy and Quality of Life The development of subcutaneous (SC) formulations for monoclonal antibodies (mAbs), as an ...
Bristol Myers Squibb Co (NYSE:BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or ...
A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...
Shares of TG Therapeutics rose after the company reported positive data for new subcutaneous formulation of a multiple sclerosis treatment. The stock climbed 12%, to $41.21, Wednesday afternoon and is ...
Investor's Business Daily on MSN
TG Therapeutics flashes an early buy signal — what drove the bullish jump
TG Therapeutics stock popped Wednesday after the biotech company said an under-the-skin shot of Briumvi appeared as safe as the IV.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results